TIDMYGEN
RNS Number : 5429G
Yourgene Health PLC
19 July 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF
THAT JURISDICTION
FOR IMMEDIATE RELEASE
Yourgene Health plc
("Yourgene", the "Group" or the "Company")
Rule 2.9 Announcement and Total Voting Rights
Manchester , UK - 19 July 2023 : Yourgene (AIM: YGEN), a leading
international molecular diagnostic group, confirms that, following
its announcement at 7.00am BST today (the "Announcement") of the
issue of 16,506,723 ordinary shares of 0.1 pence each in the
Company ("Ordinary Shares") and in accordance with Rule 2.9 of the
City Code on Takeovers and Mergers, it has in issue 3,193,466,515
Ordinary Shares.
As stated in the Announcement, the Ordinary Shares issued today
will be admitted to trading on AIM on or around 24 July 2023 and
will rank pari passu with the existing Ordinary Shares.
The Company also confirms that, in accordance with the
requirements of the FCA's Disclosure and Transparency Rule 5.6.1,
its issued share capital consists of 3,193,466,515 Ordinary Shares,
each with equal voting rights. No shares are held in treasury.
The above figure may be used by shareholders of the Company as
the denominator in the calculations by which they will determine
whether they are required to notify their interest, or a change to
their interest, in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
The International Securities Identification Number for
Yourgene's Ordinary Shares is GB00BN31ZD89.
Enquiries
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgenehealth.com
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Singer Capital Markets (Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George Tzimas
Walbrook PR Ltd (Media and Investor Relations) Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Paul McManus / Alice Woodings / Lianne Applegarth Mob: 07980 541 893 / 07407 804 654
/ 07584 391 303
About Yourgene Health
Yourgene Health is an international integrated technologies and
services business, enabling the delivery of genomic medicine. The
Group works in partnership with global leaders in DNA technology to
advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic and screening solutions,
for reproductive health and precision medicine. The Group's
portfolio of in vitro diagnostic products includes non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests and DPYD genotyping assays.
Building on our expertise in genomic technology, Yourgene's
Ranger(R) Technology offers next generation size selection with a
range of sample preparation platforms for dynamic target
enrichment. Ranger(R) Technology can be utilised to improve
workflows and performance in multiple applications including NIPT,
oncology, infectious disease testing and gene synthesis.
Yourgene Genomic Services offers a clinical service from UK and
Taiwan focusing on precision medicine and reproductive health,
including NIPT.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei (divestment pending), Singapore, the US and Canada, and
is listed on the London Stock Exchange's AIM market under the
ticker "YGEN".
For more information visit https://yourgenehealth.com/ and
follow us on twitter @Yourgene_Health.
Disclosure requirements of the City Code on Takeovers and
Mergers
Under Rule 8.3(a) of the City Code on Takeovers and Mergers
("Code"), any person who is interested in 1% or more of any class
of relevant securities of an offeree company or of any securities
exchange offeror (being any offeror other than an offeror in
respect of which it has been announced that its offer is, or is
likely to be, solely in cash) must make an Opening Position
Disclosure following the commencement of the offer period and, if
later, following the announcement in which any securities exchange
offeror is first identified. An Opening Position Disclosure must
contain details of the person's interests and short positions in,
and rights to subscribe for, any relevant securities of each of (i)
the offeree company and (ii) any securities exchange offeror(s). An
Opening Position Disclosure by a person to whom Rule 8.3(a) applies
must be made by no later than 3.30 pm (London time) on the 10th
business day following the commencement of the offer period and, if
appropriate, by no later than 3.30 pm (London time) on the 10th
business day following the announcement in which any securities
exchange offeror is first identified. Relevant persons who deal in
the relevant securities of the offeree company or of a securities
exchange offeror prior to the deadline for making an Opening
Position Disclosure must instead make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes,
interested in 1% or more of any class of relevant securities of the
offeree company or of any securities exchange offeror must make a
Dealing Disclosure if the person deals in any relevant securities
of the offeree company or of any securities exchange offeror. A
Dealing Disclosure must contain details of the dealing concerned
and of the person's interests and short positions in, and rights to
subscribe for, any relevant securities of each of (i) the offeree
company and (ii) any securities exchange offeror(s), save to the
extent that these details have previously been disclosed under Rule
8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies
must be made by no later than 3.30 pm (London time) on the business
day following the date of the relevant dealing.
If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire or control an
interest in relevant securities of an offeree company or a
securities exchange offeror, they will be deemed to be a single
person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by the offeree
company and by any offeror and Dealing Disclosures must also be
made by the offeree company, by any offeror and by any persons
acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose
relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table on
the Panel's website at www.thetakeoverpanel.org.uk, including
details of the number of relevant securities in issue, when the
offer period commenced and when any offeror was first identified.
You should contact the Panel's Market Surveillance Unit on +44
(0)20 7638 0129 if you are in any doubt as to whether you are
required to make an Opening Position Disclosure or a Dealing
Disclosure.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RTTRLMBTMTBBBPJ
(END) Dow Jones Newswires
July 19, 2023 07:21 ET (11:21 GMT)
Yourgene Health (LSE:YGEN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Yourgene Health (LSE:YGEN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
